FATE - NASDAQ

Fate Therapeutics, Inc.

FATE·NASDAQ

$2.25

-13%

HealthcareBiotechnology

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$261.67M

EPS-1.1500

P/E Ratio-1.95

Earnings Date08/05/2026

318.94M

Assets

-28%

3Y-55.0%

5Y-49.0%

10Y+236.0%

111.75M

Total Liabilities

-8%

3Y-50.0%

5Y-53.0%

10Y+410.0%

207.18M

Total Equity

-35%

3Y-57.0%

5Y-46.0%

10Y+183.0%

Fate Therapeutics, Inc. Funding & Solvency Profile

FATE · NASDAQ

Current Assets

Cash & Cash Equivalents46.63M

Net Receivables916.00K

Inventory0.00

Other Current Assets4.13M

Total Current Assets209 M

Non-Current Assets

Property, Plant & Equipment98.53M

Goodwill & Intangible Assets0.00

Long-Term Investments1.47M

Other Non-Current Assets10.23M

Total Non-Current Assets110 M

Total Assets

318.94M

Financial Health Analysis

Current Ratio

5.79x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.54x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

173 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

65% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Fate Therapeutics, Inc. Balance Sheet

FATE • NASDAQ

Fate Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	46.6M	36.1M	41.9M	61.3M	133.6M	167.3M	99.8M	190.5M	89M	88.6M	64.8M	49.1M	54M	9.1M	6.4M
Short-Term Investments	157M	243M	273.3M	374.9M	482.3M	315.6M	121.6M	10.5M	12M	3.5M	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	203.7M	279.1M	315.2M	436.2M	615.9M	482.9M	221.4M	201M	100.9M	92.1M	64.8M	49.1M	54M	9.1M	6.4M
Net Receivables	916K	3.5M	1.8M	38.5M	8.7M	5.5M	0.0	500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	916K	3.5M	1.8M	38.5M	8.7M	5.5M	0.0	500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	13.6M	0.0	8.8M	0.0	4.7M	3.7M	1.6M	1.2M	843K	760K	615K	706K	301K
Other Current Assets	4.1M	9.3M	900K	27.4M	0.0	5.9M	1M	0.0	1.6M	1.2M	843K	771K	615K	0.0	0.0
Total Current Assets	208.7M	291.9M	331.5M	502.1M	633.4M	494.3M	227.1M	205.2M	102.6M	93.3M	65.7M	49.9M	54.7M	9.8M	6.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	98.5M	110.9M	158.5M	66.1M	162.2M	99.4M	22.8M	5.1M	2.6M	1.6M	2.2M	1.2M	810K	1.2M	1M
Long-Term Investments	1.5M	27.7M	980K	4.9M	100.7M	28.7M	39.4M	2.2M	122K	122K	122K	0.0	0.0	0.0	0.0
Other Non-Current Assets	10.2M	10.2M	15.2M	132.5M	25.1M	9K	13M	526K	24K	24K	24K	132K	122K	122K	122K
Total Non-Current Assets	110.2M	148.8M	174.7M	203.5M	288M	128.1M	75.2M	7.8M	2.7M	1.7M	2.3M	1.3M	932K	1.3M	1.2M
Total Assets	318.9M	440.7M	506.2M	705.6M	921.5M	622.5M	302.3M	213M	105.3M	95M	68M	51.2M	55.6M	11.1M	7.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.7M	9.4M	4.7M	8.3M	8.6M	6.3M	5.8M	4.2M	1.7M	934K	996K	645K	682K	1.2M	1.9M
Accounts Payable	2.7M	9.4M	4.7M	8.3M	8.6M	6.3M	5.8M	4.2M	1.7M	934K	996K	645K	682K	1.2M	1.9M
Accrued Expenses	0.0	9.7M	27.5M	17.9M	42.4M	4.8M	5.3M	2.9M	1.8M	1.5M	993K	2.3M	2M	1M	0.0
Short Term Debt	4.6M	0.0	0.0	0.0	0.0	3.4M	1.7M	2.4M	0.0	8.2M	7.6M	1.5M	1.7M	1.9M	1.2M
Capital Lease Obligations (Current)	0.0	7.4M	6.2M	5.6M	5.6M	0.0	1.7M	0.0	0.0	0.0	-996K	0.0	0.0	0.0	0.0
Deferred Revenue	381K	393K	0.0	42.2M	21.5M	21.1M	2.8M	7.6M	2.1M	2.1M	2.4M	2.3M	2.1M	63K	146K
Other Current Liabilities	28.5M	11.6M	685K	40M	3.2M	50M	10.5M	10.1M	5.5M	2.5M	1.5M	130K	147K	327K	221K
Total Current Liabilities	36.1M	38.5M	39.1M	114.1M	81.3M	85.6M	27.8M	27.3M	11M	15.2M	13.4M	4.6M	4.6M	4.9M	3.7M
NON-CURRENT LIABILITIES
Long Term Debt	73.3M	0.0	0.0	0.0	0.0	0.0	0.0	12.4M	14.8M	2.5M	10.7M	18.1M	0.0	1.7M	3.6M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	27.1M	46M	3.8M	7.5M	724K	2.8M	4.9M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	2.4M	5.6M	1.3M	3.9M	25M	12.5M	702K	5.4M	1.5M	1.4M	857K	200K	135K	57.3M	51.3M
Total Non-Current Liabilities	75.7M	83.4M	98.7M	107.6M	161.3M	152.4M	29.7M	25.3M	17.1M	6.7M	16.5M	18.3M	135K	59.1M	54.9M
Capital Lease Obligations	0.0	85.3M	103.5M	109.3M	114.8M	93.9M	26.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	111.8M	122M	137.8M	221.6M	242.6M	238M	57.5M	52.6M	28.1M	21.9M	29.9M	22.9M	4.7M	63.9M	58.5M
SHAREHOLDERS' EQUITY
Preferred Stock	3K	3K	3K	3K	3K	3K	3K	3K	3K	3K	0.0	0.0	0.0	56.5M	0.0
Common Stock	115K	114K	99K	97K	96K	88K	76K	65K	53K	41K	29K	21K	20K	1K	1K
Additional Paid-In Capital	0.0	1.7B	1.6B	1.5B	1.4B	941.2M	628.2M	445.8M	295.9M	249M	180.4M	140.7M	137.3M	12.8M	686K
Retained Earnings	-1.5B	-1.4B	-1.2B	-1.1B	-769.1M	-556.9M	-383.5M	-285.4M	-218.8M	-175.8M	-142.4M	-112.4M	-86.5M	-65.6M	-51.4M
Accumulated Other Comprehensive Income/Loss	116K	268K	15K	-1.9M	-762K	70K	22K	-2K	-3K	-1K	-3.5M	-2.8M	-2.3M	-1.7M	-1.2M
Other Total Stockholders' Equity	1.7B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-56.5M	1.2M
Total Stockholders' Equity	207.2M	318.7M	368.4M	483.9M	678.8M	384.4M	244.8M	160.5M	77.2M	73.2M	38M	28.3M	50.8M	-52.8M	-50.7M
Total Equity	207.2M	318.7M	368.4M	483.9M	678.8M	384.4M	244.8M	160.5M	77.2M	73.2M	38M	28.3M	50.8M	-52.8M	-50.7M
SUMMARY
Total Liabilities & Equity	318.9M	440.7M	506.2M	705.6M	921.5M	622.5M	302.3M	213M	105.3M	95M	68M	51.2M	55.6M	11.1M	7.9M
Total Investments	158.5M	270.7M	274.3M	379.8M	583M	344.3M	161.1M	10.5M	12M	3.5M	122K	0.0	0.0	0.0	0.0
Total Debt	77.8M	85.3M	103.5M	109.3M	114.8M	97.3M	26.9M	14.9M	14.8M	10.7M	18.2M	19.6M	1.7M	3.7M	4.8M
Net Debt	31.2M	49.2M	61.7M	48M	-18.8M	-70M	-72.9M	-175.6M	-74.1M	-77.9M	-46.6M	-29.5M	-52.3M	-5.4M	-1.5M
Shares Outstanding	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697	115,329,697

SEC Filings

FATE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 12, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 27, 2025	October 26, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 14, 2025	October 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 12, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 208 filings

Related Guides

Blog Categories

Continue your FATE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.